Tejada-Pérez JJ, Vázquez-Vicente JJ, Herrera-Burgos MR, Martín-Martín FG, Parrón-Carreño T, Alarcón-Rodríguez R. Fendrix
® Vaccine Effectiveness in Healthcare Workers Who Are Non-Responsive to Engerix B
® Vaccination.
Vaccines (Basel) 2021;
9:vaccines9030279. [PMID:
33808589 PMCID:
PMC8003400 DOI:
10.3390/vaccines9030279]
[Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 03/13/2021] [Accepted: 03/16/2021] [Indexed: 11/24/2022] Open
Abstract
Hepatitis B (HBV) is a pathogen virus with transmission mechanisms that include contact with the infected blood or bodily fluids of the infected organism. Nowadays, healthcare workers are one of the most exposed groups to HBV. Conventionally, completing a vaccine series dosage with Engerix B® lowers this risk by providing workers with immunity to the virus. However, through the years, we have encountered nonresponsive health personnel to the Engerix B® vaccine; hence, the Occupational Health Service of Poniente Hospital studied the Fendrix® adjuvanted vaccine as an alternative vaccine to develop immunological responses in healthcare workers who do not respond to vaccination with Engerix B®. In our study, we employed a vaccination schedule with the Fendrix® vaccine, performing serology tests on the cases after the application of each dose. The results obtained showed humoral immunity in 92.3% of the cases, with a remarkable increase in antibody titer after the first doses. These encouraging results support the future inclusion of this vaccine as one possible alternative for the immunization to HBV for healthcare workers nonresponsive to Engerix B®.
Collapse